WillItSurvive
No grouping · subsidiary of MindMaze Therapeutics Holding SA · Switzerland

MindMaze

Swiss maker of VR/AI neuro-rehab devices for stroke and brain injury patients.

Protection under test
Assessed 29 July 2026 · Evidence as of 29 July 2026
Something worth protecting exists and is being tested right now.
On the recordSince 29 July 2026 · Checkable from Q3 2026 · Every call on the record Checkpoint: Next quarterly update on US revenue traction and cash runway under CEO Zach Henderson
The call

MindMaze holds real regulatory protection, but its bigger problem right now is cash, not AI or Penumbra.

MindMaze Therapeutics sells virtual reality therapy software that helps stroke patients recover arm movement and coordination. The company has government approvals (FDA clearance, insurance billing codes, 70+ patents) that make it hard for competitors like Penumbra or generic software makers to copy quickly, but that protection does not solve the real problem: MindMaze is losing money so fast that it needs a new financing deal every few months just to stay open, and each new deal wipes out existing shareholders. The one thing that matters is whether the company can start selling enough therapy software in the next year or two to make real money before cash runs out, because Penumbra's rival system is already winning doctors' trust in many hospitals, and free or cheap AI-powered movement apps could eventually replace MindMaze's expensive software if regulators allow it.

Why
01
AI pressure: Generic pose-estimation and movement-scoring AI models. Off-the-shelf AI motion tracking could commoditize the software layer under MindMaze's hardware, given time. Could AI do the core job? Only partly.
02
Bigger players: Penumbra REAL System. Penumbra's VR rehab system is live with a bigger stroke-intervention sales network than MindMaze has. Could a giant copy it? Probably.
03
What protects it. FDA clearances, CE marks, CPT reimbursement codes, and 70+ patents make fast copying hard for now.
What would change this call
MindMaze needs another dilutive raise within 2 to 4 quarters without US revenue growth. Would show insolvency risk is worsening rather than resolving.
Penumbra REAL System reports account wins or deployment growth in stroke-rehab clinics MindMaze targets. Would show Penumbra is converting MindMaze's target accounts.
MindMaze reports booked US recurring revenue growth for two consecutive quarters under CEO Zach Henderson. Would show commercial traction independent of new financing.
Key numbers
  • FY2025 revenue CHF 0.6M vs CHF 9.9M net loss (2026-04-15)
  • CHF 8.0M raise from Neuro.io Group, ~1yr runway (2026-05-26)
  • Market cap CHF 163M at Dec 2025 listing (2025-12-15)
Named risks
  • Burning roughly 16x revenue: CHF 9.9M net loss versus CHF 0.6M FY2025 revenue. Severity: high
  • Survival depends on repeated dilutive financing, with only about one year of runway after May 2026 raise. Severity: high
  • Equity value collapsed 80 to 95 percent from CHF 163M market cap at Dec 2025 listing to CHF 24-30M by Jul 2026. Severity: high
  • New CEO's US commercial scale-up plan (since Mar 2026) is unproven and revenue-critical. Severity: medium
  • History of a collapsed high-profile merger (Babylon Health, Aug 2023) signals execution and counterparty risk. Severity: medium
Rivals, as read in July 2026
RivalDirectionEvidence
Penumbralosing toREAL System called 'most formidable' VR rehab rival with larger distribution footprint, Mar 2026
MedtroniccontestingNamed among key neurorehabilitation-device players in a semi-consolidated market, Jul 2026
AbbottcontestingListed alongside MindMaze as neurorehabilitation-device market player, Jul 2026
Boston ScientificcontestingCited as adjacent neurostimulation incumbent in neurorehabilitation devices market, Jul 2026
Neuro Rehab VRcontestingCompetes with XR Therapy System across stroke, TBI, and orthopedic rehab, Jun 2026
XRHealthcontestingListed as top MindMaze alternative in VR digital therapeutics space
Questions people ask
Is MindMaze profitable in 2026?
No. MindMaze Therapeutics reported FY2025 revenue of just CHF 0.6 million against operating expenses of CHF 11.2 million and a net loss of CHF 9.9 million, according to its 2025 annual report published April 15, 2026. The company is burning roughly 16 times its revenue and remains far from profitability.
Has MindMaze's stock crashed?
Yes. Shares listed at around CHF 1.06 in mid-December 2025 with a market cap near CHF 163 million, then fell to a range of CHF 0.19 to CHF 0.41 by mid-July 2026, cutting market cap to roughly CHF 24 to 30 million, an 80 to 95 percent decline in about seven months.
Who owns MindMaze now?
MindMaze's technology and IP now sit inside MindMaze Therapeutics Holding SA, a Geneva-based public company formed when NeuroX Group SA (which had acquired MindMaze's assets in April 2025) combined with the previously listed Relief Therapeutics Holding SA in December 2025, trading on the SIX Swiss Exchange as MMTX.
Could AI replace MindMaze's core technology?
Not easily in the near term. MindMaze's motion-capture and movement-scoring software is the kind of workload generic AI vision models could commoditize, but its FDA clearances, six CE marks, over 70 patent families, and secured U.S. CPT Category III reimbursement codes (as of May 2026) create a regulatory moat AI-native entrants cannot quickly replicate.
Who is MindMaze's biggest competitor?
Penumbra, via its REAL System, is described in a March 2026 competitive-landscape report as the 'most formidable' direct VR upper-extremity rehabilitation rival, with a larger stroke-intervention distribution footprint than MindMaze currently has.
Did MindMaze get a new CEO recently?
Yes. MindMaze Therapeutics appointed healthtech veteran Zach Henderson, formerly of Rune Labs and PKG Health, as CEO on March 12, 2026, tasked with driving a U.S. commercial scale-up of the company's neurorehabilitation products.
Timeline
  • 2026-05-26MindMaze Therapeutics raises CHF 8.0M strategic equity financing from Neuro.io Group SA
  • 2026-04-15Publishes FY2025 annual report: CHF 0.6M revenue, CHF 11.2M opex, CHF 9.9M net loss
  • 2026-03-12Appoints Zach Henderson, ex-Rune Labs/PKG Health, as new CEO
  • 2025-12-15NeuroX Group and Relief Therapeutics combination completes, lists as MMTX on SIX
  • 2025-04-01NeuroX Group SA acquires MindMaze's assets and operations
  • 2023-08-07Planned take-private merger with Babylon Health collapses
  • 2022-02-17Secures $105M financing round led by Concord Health Partners
  • 2012-01-01MindMaze founded in Lausanne by Dr. Tej Tadi
Revision history
29 July 2026
First assessed. Protection under test. The text above is fixed as of this date and is not edited afterwards.
In the same band
Ford MotorWhirlpoolSolventum
More companies protection under test →
Sources